



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	2015_JCTI_16798
Title of the Manuscript:	Leiomyosarcoma of the kidney: case report and literature review
Type of the Article	Case Study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments	Leiomyosarcoma of the kidney 1. There are a number of typographical errors, for example a. Line 11/: "...the reported literature...." b. Line 17: "not relevant" is better statement than "irrelevant" c. Line 17: "....the patient....." d. Line 19: "....revealed a..." 2. Line 56: Both retroperitoneal and renal leiomyosarcoma are treated with surgical resection. If the tumors are not respectable, then the same palliative chemotherapy is used for both lesions. The text of the manuscript should be changed to reflect this. 3. Line 66: Please change to read that the use of	1) The words were corrected. 2) Corrected



SDI Review Form 1.6

	adjuvant chemotherapy remains “undefined” 4. Line 67: Please supply a reference to support the statement made in this sentence. What percentage develop metastatic disease – please supply data rather than the author’s opinion. 5. Why is reference 14 included? This is for a trial of chemotherapy in malignant peripheral nerve sheath tumor? This should be corrected, particularly as the authors include etoposide a drug that is not used in leiomyosarcoma. 6. Line 69 -71: There are other published data on chemotherapy in metastatic leiomyosarcoma. The authors should discuss these trials. Some would argue that a median overall survival of over 17 months is better than that for soft tissue sarcoma in general – please discuss this. 7. Please include a reference regarding the anatomic variation in the behavior of leiomyosarcoma. The authors should include such a reference, for example Bathan A et al.	3) It is what I have written. 4) I did not find a literature data about that. 5) - 6) I am discussing here a locally advanced leiomyosarcoma and not metastatic ones. 7) The subject of my manuscript which is a case report and not only a literature review is to report our experience in the treatment of an advanced renal leiomyosarcoma which was unsuccessful
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		